As activation of the MAPK pathway appears to be one of the critical elements contributing to melanoma cell proliferation and survival [38], [44] current strategies to combat resistance to BRAF inhibitor therapy are focused on combination therapies that simultaneously target more than one component of the MAPK pathway, such as BRAF and MEK (NCT01072175). Here, MAP2K7 is linked to melanoma.